• Je něco špatně v tomto záznamu ?

Waldenström's macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection

K. Growková, E. Kryukova, Z. Kufová, J. Filipová, T. Ševčíková, L. Říhová, M. Kaščák, F. Kryukov, R. Hájek,

. 2017 ; 99 (6) : 469-478. [pub] 20171010

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033734

Waldenström's macroglobulinemia (WM) is a complex disease characterized by apparent morphological heterogeneity within the malignant clonal cells representing a continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. At the molecular level, the neoplastic B cell-derived clone has undergone somatic hypermutation, but not isotype switching, and retains the capability of plasmacytic differentiation. Although by classical definition, WM is formed by monoclonal expansion, long-lived clonal B lymphocytes are of heterogeneous origin. Even more, according to current opinion, plasma cells also conform certain population with pathogenic and clinical significance. In this article, we review the recent advances in the WM clonal architecture, briefly describe B-cell development during which the molecular changes lead to the malignant transformation and mainly focus on differences between two principal B-lineage clones, including analysis of their genome and transcriptome profiles, as well as immunophenotype features. We assume that the correct identification of a number of specific immunophenotypic molecular and expression alterations leading to proper aberrant clone detection can help to guide patient monitoring throughout treatment and successfully implement therapy strategies directed against both B- and plasma cell tumor WM clones.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033734
003      
CZ-PrNML
005      
20240725142013.0
007      
ta
008      
181008s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.12959 $2 doi
035    __
$a (PubMed)28886236
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Growková, Kateřina $u Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic. Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
245    10
$a Waldenström's macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection / $c K. Growková, E. Kryukova, Z. Kufová, J. Filipová, T. Ševčíková, L. Říhová, M. Kaščák, F. Kryukov, R. Hájek,
520    9_
$a Waldenström's macroglobulinemia (WM) is a complex disease characterized by apparent morphological heterogeneity within the malignant clonal cells representing a continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. At the molecular level, the neoplastic B cell-derived clone has undergone somatic hypermutation, but not isotype switching, and retains the capability of plasmacytic differentiation. Although by classical definition, WM is formed by monoclonal expansion, long-lived clonal B lymphocytes are of heterogeneous origin. Even more, according to current opinion, plasma cells also conform certain population with pathogenic and clinical significance. In this article, we review the recent advances in the WM clonal architecture, briefly describe B-cell development during which the molecular changes lead to the malignant transformation and mainly focus on differences between two principal B-lineage clones, including analysis of their genome and transcriptome profiles, as well as immunophenotype features. We assume that the correct identification of a number of specific immunophenotypic molecular and expression alterations leading to proper aberrant clone detection can help to guide patient monitoring throughout treatment and successfully implement therapy strategies directed against both B- and plasma cell tumor WM clones.
650    _2
$a zvířata $7 D000818
650    _2
$a B-lymfocyty $x metabolismus $x patologie $7 D001402
650    _2
$a klonální evoluce $x genetika $7 D060965
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a genetická heterogenita $7 D018740
650    _2
$a genetická variace $7 D014644
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $7 D016130
650    _2
$a fenotyp $7 D010641
650    _2
$a plazmatické buňky $x metabolismus $x patologie $7 D010950
650    _2
$a signální transdukce $7 D015398
650    _2
$a tumor burden $7 D047368
650    _2
$a Waldenströmova makroglobulinemie $x diagnóza $x etiologie $7 D008258
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kryukova, Elena $u Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Kufová, Zuzana $u Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Filipová, Jana $u Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic. Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. $7 xx0320621
700    1_
$a Ševčíková, Tereza $u Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic. Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Říhová, Lucie $u Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Kaščák, Michal $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Kryukov, Fedor $u Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Hájek, Roman $u Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 99, č. 6 (2017), s. 469-478
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28886236 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20240725142007 $b ABA008
999    __
$a ok $b bmc $g 1340271 $s 1030728
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 99 $c 6 $d 469-478 $e 20171010 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace